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'It is not hyperbole to state that the 1990's will be the decade
of the taxanes'. This statement in the preface to the book by
the editors sets the scene for this small volume, the 8th in the
Basic and Clinical Oncology series published by Marcel
Dekker. Time will tell whether this is something of an
overstatement, but it certainly is true that paclitaxel is an
important new agent in cancer therapy. It was first discovered
in the bark of the western yew tree, Taxus brevifolia by a
team working under the remarkable chemist Munroe Wall,
who was also responsible for discovering camptothecin, a
lead compound in another important new drug class,
topoisomerase I inhibitors.
In the first chapter of this little book, David Kingston
reminds us of the history of paclitaxel's discovery. The toxic
properties of yew have been known for over 2000 years; he
points out that its toxicity is primarily due to taxane B. This
is structurally related to paclitaxel and is clearly cardiotoxic.
The next four chapters deal with preclinical topics including
its mechanism of action, mechanisms ofpaclitaxel's resistance
(a brief but useful review by the doyenne of this topic, Susan
Horwitz), combinations with other cytotoxic drugs and with
radiation. In some respects these chapters might prove to be
the most useful, given that these data are unlikely to be
superseded by new studies, which will certainly not be the
case for the clinical studies that are covered in the remaining
chapters.
Chapter 7 is a 30-page safety profile of paclitaxel, written
by seven employees of the Bristol Myer Squibb Company.
This is clearly a comprehensive review, and while some
readers might have preferred to have seen the chapter written
by practising oncologists, it seems to be reasonably well
balanced (although the brief remarks on docetaxel could
easily have been omitted).
The next chapter, written by Susan Arbuck from the NCI,
addresses the thorny topic of dose and schedule issues. She
acknowledges that the optimal dose schedule for paclitaxel is
still not clear; some oncologists feel that this uncertainty
relates at least in part to the speed with which the drug
received regulatory approval in the USA.
There are useful chapters describing guidelines for
administration and nursing implications and there are nine
individual chapters dealing with the activity of paclitaxel in
individual tumour types. The editors are to be congratulated
in that these contributions are reasonably up to date, with
references including 1994 abstracts. Inevitably, however, new
studies quickly supersede those which appear in books of this
kind. In the 50-page chapter on breast cancer, for example,
the remarkable degree of activity seen with paclitaxel/
doxorubicin in primary breast tumours is not reported;
similarly the activity of 96 h paclitaxel infusion in patients
who have failed therapy with the 3 h paclitaxel infusion has
also escaped.
Paclitaxel is the first taxane diterpenoid (or taxoid) to find
clinical utility, and clearly there will be others. Scattered
throughout this book there are references to the second
taxoid in clinical development, docetaxel (taxotere), including
a useful little review in the breast cancer chapter. In
retrospect it might have been helpful if these had been
brought together in a single review chapter on docetaxel so
that the volume could have covered taxoids in general.
Nevertheless, this volume will be a useful source of reference
for the busy oncologist, although in some respects it will
quickly become out of date.
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